Orphazyme AS (CHIX:ORPHAC) EPS (Basic) : kr0.00 (TTM As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS EPS (Basic)?

Orphazyme AS's basic earnings per share (Basic EPS) for the six months ended in Jun. 2022 was kr0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2022 was kr0.00.

Orphazyme AS's EPS (Diluted) for the six months ended in Jun. 2022 was kr0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was kr0.00.

Orphazyme AS's EPS without NRI for the six months ended in Jun. 2022 was kr0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2022 was 0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Orphazyme AS EPS (Basic) Historical Data

The historical data trend for Orphazyme AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS EPS (Basic) Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Basic)

Get a 7-Day Free Trial

-10,430.00

-11,470.00

-16,850.00

-22,320.00

-17,940.00

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
EPS (Basic)	Get a 7-Day Free Trial									-	-	-	-	-

Orphazyme AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Orphazyme AS's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-626.539	-	0)	/	0.035
	=	-17,901.11

Orphazyme AS's Basic EPS for the quarter that ended in Jun. 2022 is calculated as

Basic EPS (Q: Jun. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(62.983	-	0)	/	0.035
	=	1,799.51

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.00

Orphazyme AS (CHIX:ORPHAc) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Orphazyme AS EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS Headlines

No Headlines